Volume : 13, Issue : 04, April – 2026
Title:
COMPARATIVE STUDY ON SAFETY AND EFFICACY OF VONOPRAZAN AND STANDARD PROTON PUMP INHIBITORS IN PATIENTS WITH HELICOBACTER PYLORI INFECTION
Authors :
Dr. A. Sujala, Gouti Akanksha, Nameera Khatoon, Ruqsar Begum, Monika Kanchan Kumari
Abstract :
Introduction:
In this prospective study, the safety and efficacy of vonoprazan and standard proton pump inhibitors (PPIs) in the treatment of Helicobacter pylori infection are investigated. The study aims to compare the effects of these two acid-suppressing regimens on eradication rates, symptom relief, and patient-reported outcomes among individuals diagnosed with H. pylori infection. Vonoprazan and conventional PPIs are both widely used therapies as part of combination regimens for H. pylori eradication. The abstract will explore the differences in their mechanisms of acid suppression, pharmacokinetic properties, and potential side effects. Patient recruitment, study design, and outcome measures will be outlined, providing a comprehensive overview of the research methodology. Results will focus on eradication success rates, symptom improvement, patient satisfaction, and any adverse events observed during the study period. The abstract will conclude with implications for clinical practice and potential avenues for future research in this field.
Aim: To compare the Safety and Efficacy of Vonoprazan and Standard Proton pump inhibitors in Helicobacter pylori infection.
Objectives: Primary objective: To Compare the safety and efficacy of Vonoprazan and Standard Proton pump inhibitors in Helicobacter pylori infection.
Secondary objective: To check the Quality of life of patients taking Vonoprazan and Standard Proton pump inhibitors in Helicobacter pylori infection.
Methodology: The study is largely descriptive, and utilises data collected only under conditions of routine clinical care. All data collected/extracted is based solely on observations of disease management and treatment decisions made between the treating physicians and their patients.
Results And Discussion: In this study of 50 patients diagnosed with Helicobacter pylori infection, the majority were males aged 40–49 years. Patients were divided into two groups receiving either Vonoprazan-based or standard PPI-based triple therapy. Both groups showed clinical improvement, but the Vonoprazan group had more significant and complete symptom resolution. Post-treatment stool antigen tests confirmed 100% eradication in the Vonoprazan group, compared to only 76% in the PPI group. Quality of life scores, assessed through the Leeds Dyspepsia Questionnaire, revealed that all patients in the Vonoprazan group reported no dyspepsia, whereas most in the PPI group continued to experience some symptoms. These results demonstrate that Vonoprazan provided faster, more effective relief from symptoms and a higher eradication rate, likely due to its stronger and more sustained acid suppression.
Summary: The study concludes that Vonoprazan-based triple therapy is more effective than standard PPI-based therapy in the treatment of H. pylori infection. It led to complete symptom relief, higher eradication rates, and greater improvement in patient quality of life. Although both regimens were generally well tolerated, Vonoprazan demonstrated a superior safety and efficacy profile, making it a promising alternative to traditional PPI therapy for H. pylori eradication.
Key Words: Helicobacter pylori, Vonoprazan, Proton Pump Inhibitors , Eradication Therapy, Dyspepsia
Cite This Article:
Please cite this article in press A. Sujala et al., Comparative Study On Safety And Efficacy Of Vonoprazan And Standard Proton Pump Inhibitors In Patients With Helicobacter Pylori Infection., Indo Am. J. P. Sci, 2026; 13(04).
REFERENCES:
1. Lee A. spiral organisms: A microbiologic introduction to Helicobacter pylori. ScandJ Gastroenterol Suppl.1991;26(Suppl 187);9-22
2. Kandulski A, Selgrad M, Malfertheiner P. Helicobacter pylori infection: A clinical overview. Digestive and Liver Disease. 2008;40(8):619–626. doi:10.1016/ j.dld.2008.02.026.
3. Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol. 2017 Jan 28;23(4):668–675. doi:10.3748/ wig. v23.i 4.668.
4. Zuberi BF, Ali FS, Rasheed T, Bader N, Hussain SM, Saleem A. Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial. Pak J Med Sci. 2022;38(4):965-969. doi:10.12669/pjms.38.4.5436
5. Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol. 2017; 2017:4385161. doi:10.1155/2017/4385161
6. Elazazi NADA, Eltabbakh M, Hussein HM, Mahmood YM, Elwakil R. Efficacy of potassium-competitive acid blockers versus proton pump inhibitors in first- and second-line eradication regimens for Helicobacter pylori in Egyptian patients. J Transl Gastroenterol. 2024;2(3):131–138. doi:10.14218/JTG.2023.00087
7. Shinozaki S, Nomoto H, Kondo Y, Sakamoto H, Hayashi Y, Yamamoto H, et al. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J Med Sci. 2016;32(5):255–260. Doi: 10.1016/j.kjms.2016.04.009
8. Hu Y, Xu X, Liu XS, He C, Ouyang YB, Li NS, et al. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol.2023 ;13:1049908. doi:10.3389/fimmu.2022.1049908
9. Sue S, Kuwashima H, Iwata Y, Oka H, Arima I, Fukuchi T, et al. The superiority of vonoprazan-based first-line triple therapy with clarithromycin: a prospective multi-center cohort study on Helicobacter pylori eradication. Intern Med. 2017;56(11):1277–1285. doi:10.2169/internalmedicine.56.7833
10. Wang X, Teng G, Dong X, Dai Y, Wang W. Efficacy and safety of vonoprazan–amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial. Ther Adv Gastroenterol.2023;16:17562848231190976. doi:10.1177/17562848231190976
11. Chen C, Zhang D, Huang S, Zeng F, Li D, Zhang X, et al. Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial. BMC Gastroenterol.2024 ;24:131. doi:10.1186/s12876-024-03225-8
12. Li J, Lv L, Zhu Y, Zhou Z, He S. A modified 14-day dual therapy with vonoprazan and amoxicillin amplified the advantages over conventional therapies for eradication of Helicobacter pylori: a non-inferiority clinical trial. Infect Drug Resist.2023 ;16:5637–5645. doi:10.2147/IDR.S417711
13. Ashida K, Honda Y, Sanada K, Takemura Y, Sakamoto S. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy: a prospective post-marketing surveillance.2019;18(12):1255–1261. doi:10.1080/14740338.2019.1676722
14. Gunaratne AW, Hamblin H, Clancy A, Magat AJMC, Dawson MVM, Tu J, Borody TJ. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections—Exploratory study. Helicobacter. 2021;26(5):e12830. doi:10.1111/hel.12830
15. Sugimoto M, Yamaoka Y. Role of vonoprazan in Helicobacter pylori eradication therapy in Japan. Front Pharmacol.2019;9:1560. doi:10.3389/fphar.2018.01560.
16. Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2019;100(2):105–13. doi:10.1159/000502287.
17. Yu J, Lv YM, Yang P, Jiang YZ, Qin XR, Wang XY. Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection. World J Gastroenterol. 2023 May 28;29(20):3133–44. doi:10.3748/ wig .v29.i20.3133.
18. Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. J Gastroenterol Hepatol. 2025. doi:10.1111/1751-2980.12398
19. Shehryar M, Ahmad RU, Kareem HK, Khan L, Ashraf MF, Hassan A, Saeed S, Tareen HK, Nazir A, Ashraf MA. Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review. Ann Med Surg (Lond). 2022 Sep; 82:104760. Doi:10.1016/j.amsu.2022.104760.
20. Tsujimae M, Yamashita H, Hashimura H, Kano C, Shimoyama K, Kanamori A, et al. A comparative study of a new class of gastric acid suppressant agent named vonoprazan versus esomeprazole for the eradication of Helicobacter pylori. Digestion. 2016;94(4):240–6. doi:10.1159/000454762.
21. Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob.2018;17:29. doi:10.1186/s12941-018-0281-x.